Gene
PDPK1
PDPK1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (1), Target-disease associations (81), and 4 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention PDPK1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 2 of 11,460 | 0.02% |
| 2022 | 3 of 13,598 | 0.02% |
| 2021 | 5 of 15,045 | 0.03% |
| 2020 | 2 of 14,459 | 0.01% |
| 2019 | 3 of 12,159 | 0.02% |
| 2018 | 3 of 11,854 | 0.03% |
| 2017 | 4 of 11,595 | 0.03% |
| 2016 | 2 of 10,983 | 0.02% |
| 2015 | 5 of 11,395 | 0.04% |
| 2014 | 1 of 10,367 | 0.01% |
Showing 10 of 34 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Cell Signaling Technology | Reagent supplier | Clinical validation | 1 | April 16, 2014 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PDPK1 amplification | Pi3k Pathway Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
Target-disease associations (81)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Acanthosis nigricans - Insulin resistance - muscle cramps - acral enlargement | endocrine system disease | Mouse knockout (IMPC) |
| BDV syndrome | endocrine system disease | Mouse knockout (IMPC) |
| COVID-19 | infectious disease | reactome |
| Estrogen resistance syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Familial partial lipodystrophy, Köbberling type | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 81 associations.
Vendor sourcing (1)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1495C>A (p.P499T) alteration is located in exon 13 (coding exon 13) of the PDPK1 gene. This alteration results from a C to A substitution at nucleotide... | View ClinVar record SCV003553604.2 |
Trial-cited literature (37)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial. | EClinicalMedicine | 2023 | 11 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
| Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. | Endocrine reviews | 2022 | 270 |
| Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting. | Journal of cachexia, sarcopenia and muscle | 2022 | 189 |
| Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. | Exploration of targeted anti-tumor therapy | 2022 | 24 |
Showing 5 of 37 papers.
Literature-extracted relations (2)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Osteoporosis | Disease | associate |
Inhibition of 3-phosphoinositide-dependent protein kinase 1 (PDK1) can revert cellular senescence in human dermal fibroblasts. | 2020 |
| Neoplasms | Disease | associate |
Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. | 2015 |
Organizations publishing (50)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 2 | 2011 to 2015 |
| University of Oxford | Academic | 2 | 2015 to 2022 |
| Ain Shams University | Academic | 1 | 2022 |
| Beth Israel Deaconess Medical Center | Hospital | 1 | 2009 |
| Central South University | Academic | 1 | 2023 |
Showing 5 of 50 organizations.
Where PDPK1 appears
- biological_process
- cancer or benign tumor
- endocrine system disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
78 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, trial mentions, protein variant mentions, and human sample screening reference.